Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Lymphoma Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, Mantle-Cell Lymphoma, Marginal Zone Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular Antibody-Drug Conjugate ADC CD22 SMARTag™ technology TRPH-222 Escalation Expansion
Lead Scientist at UC Cancer
- Natalie Galanina, MD (ucsd)
Assistant Clinical Professor, Medicine. Authored (or co-authored) 11 research publications.
- accepting new patients
- Start Date
- Completion Date
- Triphase Research and Development III Corp.
- Phase 1
- Study Type
- Last Updated